Voyager’s Gene Therapy to Enter Phase 2/3 Trial Program for Advanced Parkinson’s Disease – Parkinson’s News Today
Parkinson’s News Today |
Voyager's Gene Therapy to Enter Phase 2/3 Trial Program for Advanced Parkinson's Disease
Parkinson’s News Today Voyager Therapeutics will soon initiate a global Phase 2/3 clinical trial program to evaluate its VY-AADC gene therapy for the treatment of advanced Parkinson's disease. The trial follows approval by the U.S. Food and Drug Administration of the company … MRI Interventions Recognizes FDA Clearance of Voyager's Investigational New Drug Application for VY-AADC … |
